NCT04610736View on ClinicalTrials.gov

TEMOkids Study : A Phase I Pediatric Study for KIMOZO, Oral Suspension of Temozolomide

PHASE1CompletedINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

March 16, 2021

Primary Completion Date

January 15, 2023

Study Completion Date

July 3, 2023

Conditions
Pediatric Cancer
Interventions
DRUG

Temozolomide Oral Suspension

One prescribed oral dose (range 75 to 200 mg/m2) once daily for 5 days

Trial Locations (11)

13005

CHU Timone Enfants, Marseille

13353

Charité University Medicine Berlin, Berlin

59000

Centre Oscar Lambret, Lille

69008

Institut d'Hématologie et d'Oncologie Pédiatrique, Lyon

69120

Hopp Children's Cancer Center Heidelberg, Heidelberg

75005

Institut Curie, Paris

94800

Gustave Roussy, Villejuif

3584 CS

Princess Maxima Center for Pediatric Oncology, Utrecht

08035

Hospital Universitari Vall d'Hebron, Barcelona

WC1N 3JH

Great Ormond Street Hospital for Children, London

SO16 6YD

Southampton General Hospital, Southampton

Sponsors

Lead Sponsor

Orphelia Pharma

Collaborators (1)

ClinSearch
All Listed Sponsors
collaborator

ClinSearch

OTHER

lead

Orphelia Pharma

INDUSTRY

NCT04610736 - TEMOkids Study : A Phase I Pediatric Study for KIMOZO, Oral Suspension of Temozolomide | Biotech Hunter | Biotech Hunter